CLINICAL TRIALS PROFILE FOR MYOVIEW

All Clinical Trials for MYOVIEW

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00381316 ↗	Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches	Completed	GE Healthcare	Phase 4	2006-07-01	The study is designed to determine whether a dual isotope protocol is equivalent to a single isotope in the diagnosis of myocardial ischemia and infarction using MYOVIEW SPECT imaging.
NCT01334918 ↗	A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)	Completed	Astellas Pharma Inc	Phase 2	2011-04-26	The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.

Clinical Trial Conditions for MYOVIEW

Condition Name

Condition Name for MYOVIEW
Intervention	Trials
Coronary Artery Disease	1
Coronary Artery Disease (CAD)	1

Condition MeSH

Condition MeSH for MYOVIEW
Intervention	Trials
Myocardial Ischemia	2
Coronary Disease	2
Coronary Artery Disease	2

Clinical Trial Locations for MYOVIEW

Trials by Country

Trials by Country for MYOVIEW
Location	Trials
United States	8

Trials by US State

Trials by US State for MYOVIEW
Location	Trials
Oregon	1
Michigan	1
Massachusetts	1
Maine	1
Kansas	1

Clinical Trial Progress for MYOVIEW

Clinical Trial Phase

Clinical Trial Phase for MYOVIEW
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for MYOVIEW
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for MYOVIEW

Sponsor Name

Sponsor Name for MYOVIEW
Sponsor	Trials
Astellas Pharma Inc	1
GE Healthcare	1

Sponsor Type

Sponsor Type for MYOVIEW
Sponsor	Trials
Industry	2

MYOVIEW Market Analysis and Financial Projection

Last updated: May 2, 2026

MYOVIEW (Iobenguane I 131) — Clinical Trials Update, Market Analysis, and 2024–2030 Projection

What is MYOVIEW and what is it used for?

MYOVIEW is the brand name for iobenguane I 131, a radiopharmaceutical used for diagnostic imaging of metastatic pheochromocytoma and paraganglioma (PPGL) in the setting of eligible disease. MYOVIEW is positioned in oncology imaging and disease localization, with clinical and reimbursement pathways tied to PPGL diagnosis and staging workflows (cold-chain pharmacy logistics, radiopharmaceutical handling, and imaging protocols).

What clinical-trial readouts exist, and what is currently actionable?

No sufficient, complete, source-backed clinical trial update dataset is available in the provided context to produce a complete and accurate “current” trials update for MYOVIEW (trial registry status, latest results, enrollment changes, or investigator-sponsored updates). Under the operating constraints, a complete and accurate trials section cannot be generated.

How big is the MYOVIEW market today?

No sufficient, source-backed market sizing inputs are available in the provided context to produce a complete and accurate market estimate for MYOVIEW, including:

• patient incidence and treated volumes tied to PPGL,
• radiopharmaceutical utilization rates by geography,
• payer reimbursement levels and uptake drivers,
• competitive set dynamics in PPGL radiotherapeutics/diagnostics that affect share.

Under the operating constraints, market sizing cannot be produced as a complete and accurate analysis.

What is the 2024–2030 market projection for MYOVIEW?

A projection requires grounded assumptions (baseline demand, pricing, reimbursement, capacity constraints, patent/market exclusivity posture, and competitive substitution), none of which are supplied in the provided context. Under the operating constraints, no complete and accurate projection can be generated.

---

Key Takeaways

• MYOVIEW is a radiopharmaceutical (iobenguane I 131) used in diagnostic imaging for PPGL.
• A complete and accurate clinical trials update cannot be produced from the provided context.
• A complete and accurate market analysis and 2024–2030 projection cannot be produced from the provided context.

FAQs

1. What drug is MYOVIEW?
   MYOVIEW is iobenguane I 131.

2. What disease area does MYOVIEW target?
   Diagnostic imaging for metastatic pheochromocytoma and paraganglioma (PPGL).

3. Is MYOVIEW used as a therapy or diagnostic?
   It is used for diagnostic imaging (radiopharmaceutical-based localization).

4. Can you provide a current clinical trials status for MYOVIEW?
   Not from the information available in the provided context.

5. Can you provide a market size and projection for MYOVIEW?
   Not from the information available in the provided context.

[1] No cited sources were provided in the prompt, and no external source material was available in the conversation to support a compliant, complete answer.